Phillips 66

▲ Bull Case

• ◆Elliott delivers Midstream separation or value-accretive spin-off (25–30% probability within 2 years). Re-rating Midstream from 10x to 11.5x EBITDA adds ~$15–20/share; full MLP parity (12x+) adds $30–50/share. Sum-of-parts math is overwhelming.
• ◆CPChem normalizes at $2B+ PSX equity income by FY2027. Chinese PE overcapacity absorbs over 4–5 years (demand growing 4%/yr globally). GC II cracker adds advantaged US Gulf Coast supply into tightening market. Incremental PSX value: $15–25/share.
• ◆Operational excellence sustains through cycle. 98–99% utilization at lowest cost/barrel since 2021. In recovery year ($18–22/bbl spreads), EPS reaches $18–22/share; PSX at 10x = $180–220/share with no structural catalyst needed.

▼ Bear Case

• ◆Crack spreads regress to $10–12/bbl from new Asian/Middle East refinery capacity (Saudi Jazan, Indian expansions: 2–3 mbpd net 2024–2027). FY2024 trough ($3.7B EBITDA) repeats or deepens; dividend sustainability becomes headline risk. Stock re-tests $110–130.
• ◆CPChem structurally impaired through FY2028. Chinese PE overcapacity (10–15MT new 2021–2024) absorbs slower than consensus. GC II cracker starts into trough market. PSX's $2.5B cumulative CPChem capex earns sub-cost-of-capital returns for 3–4 more years.
• ◆Elliott conflict turns unproductive. Boardroom tension prevents timely capital decisions. Forced Midstream separation at trough multiples (rising rates compress MLP valuations) destroys value—'doing the right thing at wrong time' costs shareholders $10–20/share.

“Central debate: Is PSX's conglomerate structure a value trap or catalyst? Bull camp: Elliott cracked the code—sum-of-parts math is overwhelming. Midstream worth $40–45B vs. ~$20–22B embedded in current enterprise value. Only question is timing. Bear camp: Conglomerate discounts persist for decades. VLO and MPC traded at lower multiples than Midstream peers for 10+ years without re-rating. PSX must execute on Midstream growth, CPChem recovery, AND Elliott resolution while managing cyclical refining with elevated leverage. Secondary debate: Is FY2025's $18–25/bbl crack spread environment the 'new normal' or temporary recovery before structural compression? This drives a $30–40/share EPS estimate swing.”

• ◆Elliott/PSX announce Midstream separation or spin-off (H2 2026 – H1 2027, 25–30% probability, +$25–55/share value impact)
• ◆CPChem quarterly equity income exceeds $500M run-rate (FY2026 Q3–Q4, 30% probability, +$12–18/share impact)
• ◆Crack spreads sustain $18–22/bbl through FY2026 (Q2–Q4 2026, 40% probability, +$8–12/share EPS beat)
• ◆European refinery asset sale driving net debt reduction (H1–H2 2026, 20% probability, +$5–10/share impact)
• ◆Share buyback acceleration ($2B+/yr) (FY2026–2027, 35% probability, +$5–8/share accretion)

• ◆Crack spreads collapse below $12/bbl (12–24 months, 20–25% probability, -$50–70/share impact from Refining EBITDA trough)
• ◆CPChem trough extends through FY2028 (24–36 months, 30–35% probability, -$15–25/share from delayed recovery)
• ◆Elliott forced separation at trough Midstream multiples (H2 2026, 15% probability, -$10–20/share SOTP destruction)
• ◆Dividend cut if FCF falls below $1.5B (12 months if crack <$10/bbl, 10–15% probability, -$15–20/share from yield loss)
• ◆Credit downgrade if leverage exceeds 4.5x normalized EBITDA (12–18 months downside scenario, 10% probability, -$10–15/share)
• ◆Renewable fuels policy reversal or LCFS reform (ongoing, 25% probability, -$3–5/share from Rodeo economics deterioration)